Di-(2-phenylethyl)phosphinic Acid | 14561-21-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Di-(2-phenylethyl)phosphinic Acid
• 英文别名: bis(2-phenylethyl)phosphinic acid；bis(2-phenylethyl)phosphonic acid；diphenethylphosphinic acid；Diphenethyl phosphinic acid；Bis-β-phenylethyl-phosphinsaeure；Bis-(2-phenylethyl)-phosphonsaeure
• CAS: 14561-21-8
• 化学式: C₁₆H₁₉O₂P
• 分子量: 274.299
• InChiKey: NIRBJNRGTKTFRV-UHFFFAOYSA-N

物化性质

• 熔点：
  95-97 °C(Solv: ethanol (64-17-5))
• 沸点：
  522.5±39.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Di-(2-phenylethyl)phosphinic Acid 在 磺酰氯 作用下， 以 四氯化碳 为溶剂， 生成 diphenethylphosphinylchloride
  参考文献：
  名称：

  Amino acid derivatives and antihypertensive drugs containing them

  摘要：

  N-末端磷二肽具有降压作用。

  公开号：

  US04536395A1
• 作为产物：
  描述：

  bis(2-phenethyl)phosphine 在 氢氧化钾 、 双氧水 、 二甲基亚砜 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 Di-(2-phenylethyl)phosphinic Acid
  参考文献：
  名称：

  3-巯基1,1-二氧化物与PH酸的反应

  摘要：

  DOI：

  10.1007/bf02251545

文献信息

• Amino acid derivatives, methods of preparing said derivatives and
  申请人：Ajinomoto Company Incorporated

  公开号：US04472381A1

  公开（公告）日：1984-09-18

  The present invention relates to an amino acid derivative represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent hydroxyl, alkyloxy, aryloxy, arylkyloxy, alkyl, aryl, or aralkyl; R.sub.3, R.sub.5, R.sub.8 and R.sub.11 are hydrogen or alkyl; R.sub.4, R.sub.7 and R.sub.10 are hydrogen, or substituted or unsubstituted alkyl, aryl or aralkyl; R.sub.6 and R.sub.9 are hydrogen, alkyl, aryl, or aralkyl; R.sub.12 is hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl-, aryl- or aralkyl amino; and R.sub.6 and R.sub.7 combined together, and R.sub.9 and R.sub.10 combined together independently may form a substituted or unsubstituted alkylene bridge. The present invention also relates to a method of preparing said amino acid derivatives, and to anti-hypertensive drugs containing them.

  本发明涉及一种由以下式表示的氨基酸衍生物##STR1##其中R.sub.1和R.sub.2代表羟基、烷氧基、芳基氧基、芳基烷氧基、烷基、芳基或芳基烷基；R.sub.3、R.sub.5、R.sub.8和R.sub.11为氢或烷基；R.sub.4、R.sub.7和R.sub.10为氢，或取代或未取代的烷基、芳基或芳基烷基；R.sub.6和R.sub.9为氢、烷基、芳基或芳基烷基；R.sub.12为羟基、烷氧基、芳基氧基、芳基烷氧基、氨基、单烷基或双烷基、芳基或芳基氨基；以及R.sub.6和R.sub.7结合在一起，R.sub.9和R.sub.10独立地结合在一起可能形成取代或未取代的烷基桥。本发明还涉及制备所述氨基酸衍生物的方法，以及含有它们的抗高血压药物。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05142056A1

  公开（公告）日：1992-08-25

  A retroviral protease inhibiting compound of the formula A--X--B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.

  一种抑制逆转录病毒蛋白酶的化合物，其化学式为A--X--B或其药用盐、前药或酯，其中X为连接基；A为（1）取代氨基，（2）取代羰基，（3）官能化亚胺基，（4）官能化烷基，（5）官能化酰基，（6）官能化杂环基或（7）官能化（杂环）烷基；B为（1）取代羰基，独立定义如本文所述，（2）取代氨基，独立定义如本文所述，（3）官能化亚胺基，独立定义如本文所述，（4）官能化烷基，独立定义如本文所述，（5）官能化酰基，独立定义如本文所述，（6）官能化杂环基，独立定义如本文所述或（7）官能化（杂环）烷基，独立定义如本文所述。
• Phosphorous-containing cysteine and serine protease inhibitors
  申请人：Cephalon, Inc.

  公开号：US05639732A1

  公开（公告）日：1997-06-17

  The present invention is directed to novel phosphorous-containing inhibitors of cysteine or serine proteases. Methods for the use of the protease inhibitors are also described.

  本发明涉及一种新型含磷半胱氨酸或丝氨酸蛋白酶抑制剂。还描述了使用蛋白酶抑制剂的方法。
• Alkylation of phosphine PH3 generated from red phosphorus
  作者：Delphine Semenzin、Guita Etemad-Moghadam、Dominique Albouy、Max Koenig

  DOI：10.1016/s0040-4039(00)76889-4

  日期：1994.5

  The generation of phosphine PH3 by alkaline hydrolysis of red phosphorus is realized. The subsequent alkylation of PH3 by terminal alkenes and alkynes in basic media leading to the corresponding aliphatic and vinylic phosphine derivatives can occur by two-steps or one-pot reaction by a Michael-like reaction mechanism.

  实现了通过红磷的碱性水解生成膦PH 3。在碱性介质中，末端烯烃和炔烃随后将PH 3烷基化，生成相应的脂族和乙烯基膦衍生物，可通过两步反应或一锅反应通过迈克尔样反应机理进行。
• Intermediates for preparating non-peptide retroviral protease inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0839798A2

  公开（公告）日：1998-05-06

  Intermediates, for preparing non-peptide retroviral protease inhibitors, said intermediates having the formula: or an acid addition salt thereof or an N-protected derivative thereof wherein at each occurrence the N-protecting group is independently selected from the group consisting of formyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzyl and isopropylaminocarbonyl; or said intermediates being selected from: (2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; 2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and 2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; or an acid addition salt thereof.

  用于制备非肽类逆转录病毒蛋白酶抑制剂的中间体，所述中间体具有以下式子： 或其酸加成盐或其 N-保护衍生物，其中每次出现时，N-保护基独立选自甲酰、乙酰、特戊酰、叔丁基乙酰、叔丁氧羰基、苄氧羰基、苄基和异丙氨基羰基组成的组；或所述中间体选自以下物质 (2S,3R,4S,5S)-2,5-二(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4R,5S)-2-(N-(叔丁氧基)羰基)氨基)-5-(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； 2-(N-苄基-N-(苄氧羰基)氨基)-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物； 2-氨基-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物；以及 2,5-二（叔丁氧羰基氨基）-1,6-二苯基-3-己烯-3,4-氧化物； 或其酸加成盐。